ADMA BIOLOGICS INC

Adma Biologics dips 0.54% as it skirts below its 200‑day SMA; despite a 12.9% month‑to‑date rally, the biotech’s niche plasma therapy and volatile market pose mixed signals for investors.

Adma Biologics shares dip 1.96% at $11.01 but have surged 12% mtd – track its market cap, volume, and 200‑day SMA to gauge future upside.

Adma Biologics surges, outpacing peers with steady 18% monthly growth and low valuation—ideal value play in the immunology biopharma space.

ADMA Biologics shares rise 3.65% to $11.23, aligning near its 200‑day SMA and outpacing peers; explore its plasma‑derived drug pipeline and market‑cap strength.